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Severe acute respiratory syndrome (SARS) has
caused a major epidemic worldwide. A novel coronavirus
is deemed to be the causative agent. Early diagnosis can
be made with reverse transcriptase-polymerase chain
reaction (RT-PCR) of nasopharyngeal aspirate samples.
We compared symptoms of 156 SARS-positive and 62
SARS-negative patients in Hong Kong; SARS was con-
firmed by RT-PCR. The RT-PCR–positive patients had sig-
nificantly more shortness of breath, a lower lymphocyte
count, and a lower lactate dehydrogenase level; they were
also more likely to have bilateral and multifocal chest radi-
ograph involvement, to be admitted to intensive care, to
need mechanical ventilation, and to have higher mortality
rates. By multivariate analysis, positive RT-PCR on
nasopharyngeal aspirate samples was an independent
predictor of death within 30 days. 
S
evere acute respiratory syndrome (SARS) is an emerg-
ing infectious disease worldwide. By May 28, 2003, a
total of 745 patients had died of SARS and 8,240 persons
were infected. At the same time, 270 patients had died of
SARS and 1,730 were diagnosed in Hong Kong. As
defined by the Centers for Disease Control and Prevention
(CDC), a suspected SARS patient is a person with a tem-
perature >38°C; clinical findings such as cough, shortness
of breath, and difficulty breathing, together with history of
travel to an area with documented local transmission or
close contact with a suspected SARS patient within 10 days
of symptoms onset. A probable SARS case also requires
radiologic evidence of pneumonia or respiratory distress
syndrome or autopsy findings consistent with pneumonia
or respiratory distress syndrome without an identifiable
cause (1). Because of this nonspecific definition, many
non-SARS patients may be mislabeled as having SARS.
The discovery of coronavirus as the causative agent and the
establishment of laboratory tests for coronavirus have
aided the research direction. However, these tests only act
as supplementary aids to the diagnosis of suspected and
probable cases of SARS. The diagnostic tools for coron-
avirus infection include reverse transcriptase-polymerase
chain reaction (RT-PCR), serologic testing, electron
microscopy, and viral culture. Afourfold increase in paired
serologic test results suggest highest sensitivity and is
regarded as the standard criterion for diagnosis. Studies
have shown that antibodies against coronavirus are usually
present 14–21 days after onset of symptoms. Electron
microscopy and viral culture for coronavirus are specific,
but the sensitivity is low. The sensitivity of the RT-PCR for
coronavirus in nasopharyngeal aspirate (NPA) samples
ranges from 32% to 50% at the beginning of an illness and
in stool samples is 97% at a mean of 14.2 days (2,3). The
variation in sensitivity makes it difficult for the RT-PCR to
be the standard criterion for diagnosis. Though the sensitiv-
ity is less than perfect, the assay can be used as a tool for
early diagnosis. Until now, no data existed regarding the
clinical course and outcome of SARS patients with NPA
samples that were positive or negative for coronavirus by
RT-PCR. We compared the epidemiologic, clinical, labora-
tory, and radiologic differences between RT-PCR–positive
SARS and RT-PCR–negative SARS samples. We also
looked for possible microbiologic evidence of coronavirus
infection in RT-PCR–negative patients.
Methods
Patients
Two hundred sixty-seven patients fulfilling CDC case
definition for suspected or probable SARS were admitted
to the isolation wards of the Princess Margaret Hospital
from February 26, 2003, to March 31, 2003. RT-PCR on
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Investigation
Routine hematologic, biochemical, and microbiologic
tests were performed for all patients. NPA samples were
examined by rapid immunofluorescence antigen detection
methods for viral cell culture and for common respiratory
virus, including influenza viruses A and B; adenovirus;
respiratory syncytial virus; and parainfluenza virus types
1, 2, and 3. Sputum samples were screened for bacterial
and mycobacterial infection by conventional microscopic
identification (Gram staining and acid-fast staining) and
culture methods (blood, chocolate, MacConkey, and
Löwenstein-Jensen media). Serologic testing for
Mycoplasma pneumoniae, Chlamydia pneumoniae, and C.
psittaci was performed. Urinary antigen detection tests
were used to detect Legionella pneumophila and
Streptococcus pneumoniae in some patients. Paired serum
samples were taken 10–14 days apart to assess the serolog-
ic response to coronavirus by immunofluorescence assay
(IFA). All chest radiographs were classified according to
their laterality and extent of involvement. 
Qualitative RT-PCR Testing
The NPAsample collected from patients was added into
a sterile vial containing 2 mL of viral transport medium
and then transported on ice (4°C) to the Public Health
Laboratory Centre, Government Virology Unit (GVU) of
Hong Kong. Total RNA from 140 µL of each NPA sample
was extracted by a QIAamp viral RNAMini kit (QIAGEN,
Valencia, CA), as instructed by the manufacturer and elut-
ed in 60 µL of buffer. A total of 4.2 µL of eluted RNA was
reverse-transcribed with use of reverse transcriptase
(Applied Biosystem, Foster City, CA) in a 20-µL reaction
containing 2.5 µM (final concentration) of random hexam-
er. The mixture was incubated at room temperature for 10
min and then at 42°C for 15 min. The reaction was stopped
at 95°C for 5 min and then chilled in ice. The primers used
for amplification, COR-1 and COR-2, were targeted at the
coronavirus polymerase gene designed by GVU: sense 5′
CAC CGTTTC TAC AGG TTAGCTAAC GA3′and anti-
sense 5′ AAA TGT TTA CGC AGG TAA GCG TAA AA
3′, with expected product size of 311 bp. Five microliters
of cDNA was amplified in 45 µL of master mixture con-
taining 5 µL of 10X PCR buffer (Amersham Pharmacia
Biotech, Piscataway, NJ), 1 µL of 2 5 mM extra MgCl2, 4
µL of deoxynucleoside triphosphates (dNTPs) (2.5 mM
each), 0.5 µL of each primer, 0.3 µL of Taq polymerase (5
U/mL), and 33.7 µL of molecular grade water. One posi-
tive control and one negative control were included in each
PCR assay. Reactions were performed in a thermocycler
(GeneAmp PCR System 9700, Applied Biosystem) with
the following conditions: at 94°C for 3 min, followed by
45 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for 1 min,
and 72°C for 7 min.  PCR products were analyzed by gel
electrophoresis.
Treatment
All patients received treatment according to a standard
protocol. Either a β-lactam plus β-lactamase inhibitor or
third-generation cephalosporin in combination with a
macrolide or a fluoroquinolone was given to the patient at
admission. Per the recommendation of the Hospital
Authority of Hong Kong, an antiviral drug (ribavirin 24
mg/kg/day intravenously, together with hydrocortisone 10
mg/kg/day) was administered if the symptoms did not
respond within 48 h (The recommendations were found
available at: URL: http://www.ha.org.hk/hk/hesd/
nsapi/?Mlval=ha_view_content&c_id=122711&lang=E.
However, the recommendations have since changed and
are available at: URL: http://www.ha.org.hk/hesd/
nsapi/?MIval=ha_view_content&c_id=123510&hesd_lan
g=E). Methylprednisolone, in the form of two to three
pulsing doses of 500 mg to 1,000 mg a day intravenously,
was administered to those with a persistent fever, radiolog-
ic evidence progression of lung infiltrates, or signs of res-
piratory distress despite the initial antiviral-hydrocortisone
combination.
Statistical Analysis
Bivariate analysis was performed for epidemiologic,
clinical, laboratory, radiologic data, and outcomes by using
RT-PCR results as the dependent variable. Data of contin-
uous variables were expressed as mean and standard devi-
ation. Chi-square test was used for categorical variables,
and the unpaired Student t test was performed for continu-
ous variables. All significant factors for death with a p
value <0.1 were pooled into a multivariate logistic regres-
sion model with backward stepwise analysis to identify the
independent predictors for the clinical outcome. A p value
<0.05 (two-tailed) was assumed to be statistically signifi-
cant. All analyses were performed with the SPSS version
10.0 software (SPSS Inc, Chicago, IL).
Results
Demographic Findings
On admission, nasopharyngeal RT-PCR was performed
on 90 male and 128 female patients (mean age 39.6 ± 14
years). All patients, except six, were Chinese; two were
Indonesian, and four were Filipino. Twenty-one of the
patients (10%) were healthcare workers, including 5 clini-
cians, 9 nurses, 5 ward assistants, and 2 allied health work-
ers who worked in the SARS wards. Forty-one patients
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areas in the 2 weeks before admission; the most common
areas visited were in the southern part of China. Our cohort
consisted of patients (46.8%) from a local housing estate,
the Amoy Gardens. Ten patients (4.6%) had one or more
coexisting medical problems: diabetes mellitus (3 cases), a
history of cerebrovascular disease (4 cases), ischemic heart
disease (3 cases), chronic rheumatic heart disease (1 case),
hypertrophic obstructive cardiomyopathy (1 case), sick
sinus syndrome (1 case), cirrhosis of the liver secondary to
chronic hepatitis B (1 case), bronchiectasis (1 case), end-
stage renal disease (1 case), Sjögren syndrome (1 case),
and nasopharyngeal carcinoma (1 case). The proportions of
patients from Amoy Gardens that were RT-PCR positive
(48%) and negative (45.7%) were not significantly differ-
ent (p = 0.76). Likewise, the proportions of healthcare
workers (p = 0.28) or patients with coexisting conditions (p
= 0.83) did not differ significantly.
RT-PCR Results
NPA samples for RT-PCR were taken from all patients
at admission; samples from 156 patients (71.6%) were
positive. The mean time from disease onset to sample col-
lection was 4.4 ± 2.3 days. No significant difference in the
mean sampling time was found between RT-PCR–positive
or –negative patients. The optimal time for sample collec-
tion was day 8–10 when 13 of 14 patients (92.9%) were
positive (Figure).
Symptoms and Laboratory Findings
The most common clinical features for both RT-
PCR–positive and –negative cases included fever, chill,
malaise, myalgia, cough, rigor, and headache (Table 1).
Shortness of breath and dizziness were significantly high-
er in RT-PCR–positive patients in bivariate analysis. Vital
signs taken on admission (temperature, heart rate, and sys-
tolic and diastolic blood pressure) were similar between
the two groups. Common laboratory findings included
anemia with hemoglobin level <12 g/dL (14.7%), lym-
phopenia with leukocyte count <4 x 109/L (72%), throm-
bocytopenia with platelet count <150 x 109/L (52.3%),
hypokalemia with plasma potassium level <3.5 mmol/L
(41.3%), hyponatremia with plasma sodium level <135
mmol/L(61.5%), and elevated levels of lactate dehydroge-
nase >230 U/L (46.6), alanine transaminase > 40 U/L
(30.8%), and C-reactive protein (77.8%). By bivariate
analysis, lymphopenia and elevated lactate dehydrogenase
level on admission were significantly different between
RT-PCR–positive and –negative patients (Table 2).
Serologic Test Results
Eighty-seven NPA RT-PCR–positive patients and 33
RT-PCR–negative patients had serologic tests on their
paired serum samples 10–14 days apart. Of the positive
RT-PCR patients, 74 patients (85.1%) had total antibodies
detected by IFA, while serologic tests for 25 patients
(75.8%) in the RT-PCR–negative group were positive.
Results for 13 patients in the RT-PCR–positive group and
8 patients in the RT-PCR–negative group were negative.
Radiologic Findings
Initial chest radiographs for 210 patients (96.3%) were
abnormal. Sixty-five (41.7%) RT-PCR–positive patients
and 13 (21%) RT-PCR–negative patients had bilateral
chest involvement shown by radiograph. Multifocal radio-
logic involvement was found in 74 (47.4%) RT-PCR–pos-
itive patients and 15 (24.2%) RT-PCR–negative patients.
By bivariate analysis, RT-PCR–negative patients were less
likely to have abnormal bilateral (p = 0.01) and multifocal
(p = 0.003) radiographs. 
Outcomes
The overall 30-day mortality rate was 10.1% (22
patients). Fifty-two (23.9%) patients required intensive-
care unit (ICU) admission, and 43 patients (19.7%) need-
ed mechanical ventilation. In nine (4.1%) patients, acute
renal failure further complicated SARS. When compared
to the RT-PCR–negative patients, the RT-PCR–positive
patients were more likely to need treatment in the ICU (p
= 0.002), require mechanical ventilation (p = 0.008), and
die (p = 0.044) (Table 3).
Predictors of Mortality
Admission parameters, including epidemiologic data,
vital signs, and laboratory and chest radiographic findings,
were analyzed separately. By bivariate analysis, factors
associated with death were age >60 (p = 0.037), male sex
(p = 0.007), major coexisting medical conditions (p =
0.001), shortness of breath (p = 0.005), total leukocyte
count >4.0 x 109/L (p = 0.041), bilateral chest radiographic
involvement (p = 0.046), RT-PCR positivity on NPA sam-
ples (p = 0.034), and pulsing doses of steroid (p = 0.001).
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Figure. Percentage of reverse transcription polymerase chain
reaction (RT-PCR) positivity at different times of sample collection
after onset of symptoms.By multivariate analysis, independent predictors of 30-day
mortality were RT-PCR positivity on NPA samples (odds
ratio [OR] 6.4; 95% confidence interval [CI] 1.1 to 38.0; p
= 0.038), shortness of breath on admission (OR 3.9; 95%
CI 1.2 to 12.3; p = 0.02), presence of important coexisting
condition (OR 13.4; 95% CI 3.1 to 58.2; p = 0.001), total
leukocyte count >4.0 x 109/L (OR, 6.94; 95% CI 1.18 to
41.6; p = 0.033), and pulsing doses of methylprednisolone
(OR 26.0; 95% CI 4.4 to 154.8; p = 0.001) (Table 4).
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Table 1. Symptoms of 218 patients with severe acute respiratory syndrome  
Symptoms 
Positive RT-PCR for coronavirus 
n=156 (%) 
Negative RT-PCR for coronavirus  
n=62 (%)  p value 
Time from symptoms onset to 
sample collection (days) 
4.5 ± 2.2  4.2 ± 2.4  0.366 
Fever  155 (99)  60 (97)  0.139 
Chill  120 (77)  51 (82.3)  0.388 
Malaise  103 (66)  34 (54.8)  0.123 
Myalgia  84 (53.8)  30 (48.4)  0.467 
Cough  66 (42.3)  27 (43.5)  0.867 
Rigor  65 (41.7)  27 (43.5)  0.800 
Headache  49 (31.4)  25 (40.3)  0.210 
Anorexia  37 (23.7)  14 (22.6)  0.858 
Sputum  28 (18)  13 (21)  0.607 
Shortness of breath  36 (23)  5 (8.1)  0.012 
Dizziness  23 (14.7)  17 (27.4)  0.029 
Diarrhea  22 (14.1)  9 (14.5)  0.937 
Sore throat  21 (13.5)  10 (16.1)  0.611 
Runny nose  15 (9.6)  9 (14.5)  0.297 
Chest pain  13 (8.3)  8 (12.9)  0.302 
Vomiting  12 (7.7)  5 (8)  0.926 
Palpitation  2 (1.3)  2 (3.2)  0.320 
Hemoptysis  1 (0.6)  1 (1.6)  0.497 
Confusion  1 (0.6)  1 (1.6)  0.497 
aFisher exact test was applied if p value was <5; RT-PCR, reverse transcription polymerase chain reaction; p values in bold are significant. 
Table 2. Vital signs and laboratory findings in 218 patients with severe acute respiratory syndrome 
 
Positive RT-PCR for coronavirus 
(n = 156) 
Negative RT-PCR for coronavirus 
(n = 62)  p value 
Vital sign upon admission       
Temperature (°C)  38.5 ± 0.9  38.4 ± 0.9  0.774 
Heart rate  95 ± 14  98 ± 16  0.571 
Systolic blood pressure  127 ± 18  130 ± 19  0.503 
Diastolic blood pressure  71 ± 11  73 ± 12  0.450 
Laboratory findings upon admission       
Hemoglobin level (g/dL)  13.3 ± 1.4  13.0 ± 1.6  0.160 
Leukocyte count (x 10
9/L)  5.5 ± 2.7  5.5 ± 1.9  0.954 
Neutrophil count (x 10
9/L)  4.3  ± 2.6  4.2 ± 2.3  0.885 
Lymphocyte count (x 10
9/L)  0.8 ± 0.3  0.9 ± 0.3  0.045 
Platelet count (x 10
9/L)  155 ± 55  166 ± 50  0.137 
Prothrombin time (sec)  12 ± 2  12 ± 1  0.396 
Activated partial thromboplastin time (sec)  35 ± 10  33 ± 5  0.094 
Sodium level (mmol/L)  134 ± 4  134 ± 3  0.423 
Potassium level (mmol/L)  3.6 ± 0.5  3.5 ± 0.4  0.787 
Urea level (mmol/L)  3.7 ± 1.8  3.6 ± 4  0.200
a 
Creatinine level (mmol/L)  74 ± 19  80 ± 79  0.885
a 
Albumin level (g/L)  37± 4  38 ± 5  0.112 
Globulin (g/L)  33 ± 5  33 ± 4  0.737 
Bilirubin (mmol/L)  9 ± 6  8 ± 5  0.798 
Alkaline phosphatase (IU/L)  75 ± 58  67 ± 33  0.245
a 
Alanine aminotransferase (IU/L)  43 ± 41  33 ± 30  0.051
a 
Creatinine phosphokinase (IU/L)  422 ± 1987  189 ± 391  0.118
a 
Lactate dehydrogenase (IU/L)  287 ± 141  208 ± 67  0.001
a 
aComparison made after log-transformation of data; RT-PCR, reverse transcription polymerase chain reaction; p values in bold are significant. Discussion
In general, the epidemiologic background, clinical
presentation, laboratory findings, and radiologic findings
of our patients were similar to those of other reports (3–5).
The clinical features of our cohort were rather nonspecific,
with fever, chills, malaise, and myalgia being the most
common. Radiologic features of our patients were similar-
ly nonspecific. Anemia, lymphopenia, and thrombocytope-
nia were common on admission. These symptoms might
reflect peripheral consumption or bone marrow suppres-
sion by the infection. Elevation of alanine transaminase, C-
reactive protein, and lactate dehydrogenase levels was fre-
quently observed; this finding might indicate extensive tis-
sue damage. 
Currently, the definition of SARS is mainly clinical,
and diagnosis is made by exclusion of pneumonia from
other known causal agents. However, patients with similar
clinical scenarios may not be infected by the same agent,
and placing them in the same location may spread infec-
tion. Unfortunately isolating every patient is not possible,
especially with a large cohort. An early, rapid, and reliable
test is needed. After coronavirus was recognized as the
putative agent for SARS, diagnostic tests have burgeoned
rapidly over the past 2 months. However, serologic tests
cannot offer an early diagnosis since, despite their remark-
able specificity, they require approximately 3 weeks for
the total antibodies to become detectable (2). Electron
microscopy and viral culture are not sensitive and conven-
ient enough for general use. Inevitably, clinical character-
istics are used solely for the diagnosis of SARS, despite
the condition’s nonspecific nature. 
RT-PCR for coronavirus on NPA samples appears to be
the best supportive test for an early and firm diagnosis.
However, the sensitivity of this test varies, and standardi-
zation of the test has not been unified. The test we used
was qualitative and had good sensitivity (71.6%). In our
study, the mean time between onset of symptoms and sam-
ple collection was 4.3 days. Peiris et al. reported that the
sensitivity for RT-PCR was 32% at a mean 3.2 days after
onset (3). In our study, the best time for sampling was on
days 8 to 10 after onset of symptom. During that period,
>90% of the samples were positive. However, since the
condition of SARS patients deteriorated both clinically
and radiologically during this time, waiting 8–10 days to
make a firm diagnosis or to plan for appropriate therapy is
not possible (3). The mean time of sample collection did
not differ significantly between RT-PCR–positive or –neg-
ative patients, suggesting that the difference in outcomes
between these two groups could not be explained by the
discrepancy in the duration of their symptoms before
admission. Whether the difference in primers used in the
RT-PCR testing or infection by a another agent, such as
metapneumovirus or Chlamydia species (6), could also
contribute to the discrepancy in sensitivity is not known.
Peiris et al. reported that the sensitivity of stool samples
for RT-PCR tests was 97% (mean of 14.2 days) (3).In our
study, the overall positive rate was 30%. However, RT-
PCR was performed on stool specimens only when diar-
rhea developed in patients.  Inconsistency in the timing of
sample collection might also contribute to the low positive
rate. In patients with negative RT-PCR results on NPA
samples, none had a stool sample positive by RT-PCR.
Hence, RT-PCR on stool specimen could not provide an
early diagnosis of coronavirus infection in our cohort. 
Patients with a positive RT-PCR result on admission
had adverse outcomes in term of survival, ICU care, and
assisted ventilation, when compared to patients with nega-
tive RT-PCR results. Therefore, the patients with over-
whelming disease had more viral shedding, which may
have been more readily detected. Despite the satisfactory
sensitivity that we demonstrated, the test might not provide
the information for quantitative analysis. Hence, a nega-
tive result might not represent low viral load in patients
and vice versa. A quantitative RT-PCR could give us some
idea as to the correlation between the viral concentration
and disease progression. Peiris et al. reported that the max-
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Table 3. Clinical progress and outcome on day 30 after admission 
Clinical progress/outcome 
Positive RT-PCR for coronavirus 
n=156 (%) 
Negative RT-PCR for coronavirus 
n=62 (%)  p value 
Patients requiring ICU care  46 (29.5)  6 (9.7)  0.002 
Patients requiring mechanical ventilation  38 (24.4)  5 (8.1)  0.008
a 
Patients developing acute renal failure  8 (5.1)  1 (1.6)  0.451
a 
Death  20 (12.8)  2 (3.2)  0.044
a 
aFisher exact test was applied if number was <5; RT-PCR, reverse transcription polymerase chain reaction. 
Table 4. Multivariate analysis on risk factors associated with 30-day mortality
a 
Risk factors  Adjusted OR (95% CI)  p value 
Significant coexisting conditions   13.4 (3.1 to 58.2)  0.001 
Shortness of breath on admission   3.9 (1.2 to 12.3)  0.020 
Total leukocyte count >4.0 x10
9/L at admission  6.94 (1.18 to 41.6)  0.033 
Positive RT-PCR on NPA  6.4 (1.1 to 38.0)  0.038 
Use of pulsing doses of steroid  26.0 (4.4 to 154.8)  0.001 
aOR, odds ratio; CI, confidence interval; RT-PCR, reverse transcription polymerase chain reaction; NPA, nasopharyngeal aspirates. 1386 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 9, No. 11, November 2003
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imal viral replication by quantitative RT-PCR occurred by
approximately day 10, but the clinical worsening seemed
to lag behind this peak (3). Although we could not quanti-
fy the maximal viral shedding, the maximal RT-PCR posi-
tivity did fall on approximately day 10. Peiris et al. also
demonstrated that an initial positive RT-PCR result had no
correlation to development of an acute respiratory distress
syndrome. In our multivariate analysis model, however,
initial RT-PCR positivity on NPA was an independent pre-
dictor for a worse outcome, rather than a previously report-
ed factor, such as a coexisting condition (3–5). Although
quantitative RT-PCR was not performed on samples from
our patients, since the test was not available at that time, a
qualitative RT-PCR result might alert the clinician to
watch out for possible clinical deterioration, especially
when the former test was in its infancy for common use.
The relationship between viral load on NPA and outcome
should be further investigated. 
The clinical outcomes of RT-PCR–positive patients are
worse in general when compared to RT-PCR–negative
patients, and their chest radiographs show more bilateral
and multifocal haziness. A higher level of lactate dehydro-
genase was observed in the RT-PCR–positive patients,
which might indicate more extensive lung tissue injury, as
indicated in other SARS patients with poor outcome (4).
Whether the lower lymphocyte count in RT-PCR–positive
patients suggests more extensive viral infection remains to
be clarified. Use of pulsing doses of methylprednisolone
could result in clinical improvement and the resolution of
radiologic infiltration in some of our patients. However, its
immunosuppressive effect could also predispose a patient
to secondary nosocomial infection and subsequent death.
How to handle negative results in RT-PCR testing is a
problem. In accordance with the World Health
Organization’s (WHO) recommendations, a negative result
has at least two possibilities (7). First, it may indicate a
false-negative result caused by low viral load or inappro-
priate timing of sample collection. Second, another infec-
tious or a noninfectious agent may be the cause of SARS
instead of coronavirus. Finally, a negative RT-PCR result
on admission may indicate early elimination of the virus
by an effective and harmonious immunologic response.
Serologic tests are thus important in identifying SARS
infections, although the diagnosis could not be made early
enough to prompt an appropriate action. In our patients,
RT-PCR and serologic results were in concordance. The
sensitivity of RT-PCR test was 74.7% when an antibody
test was used as a standard, which can be explained by the
variation in the technique and timing of sampling. The
optimal timing for the RT-PCR test is unknown. The prob-
lem of finding an appropriate sampling time was taken in
account for the RT-PCR–positive patients with negative
serologic results, since they suggested that antibodies
could be detected at 21 days (8)instead of 10–14 days, as
in our cohort. In addition, the PCR test may be overly sen-
sitive, which may be why WHO has advised clinicians to
confirm a positive RT-PCR result by repeating the test with
the original sample or testing the sample in a secondary
laboratory so as to increase its specificity (8).
Results of both RT-PCR and antibody tests were nega-
tive in eight patients; all of these patients had signs and
symptoms that were clinically, radiologically, or biochem-
ically well-matched with SARS, and they were given treat-
ment, including ribavirin and steroid. Pulsing doses of
steroid was also used in two of these patients. In addition
to the sample timing, these patients could represent a
milder spectrum of the disease with little antibody stimu-
lation or inconspicuous coronavirus RNA level, or simply
infection other than coronavirus. Antibody production may
have been suppressed because of steroid administration.
Because RT-PCR testing has not been standardized, the
test still varies in sensitivity and specificity, and we are still
confronted with a clinical dilemma in terms of infection
control and management. Furthermore, the controversy of
medication in the management of SARS has never been
settled. Current treatment guidelines proposed by the
Hospital Authority of Hong Kong are still in use despite
the adverse effects of the suggested treatment (The recom-
mendations were found available at: URL:
http://www.ha.org.hk/hk/hesd/nsapi/?Mlval=ha_view_con
tent&c_id=122711&lang=E.)Without a reliable and rapid
RT-PCR test for diagnosis, patients mislabeled as having
SARS will be offered treatment that they do not need. 
Our results indicate that a positive nasopharyngeal RT-
PCR result on admission, from the current standard, should
raise the possibility of SARS in appropriate clinical set-
tings and should alert the clinician of the possible clinical
deterioration of the patient. Furthermore, clinicians should
consider repeating the qualitative RT-PCR test or perform-
ing quantitative RT-PCR test for a previously RT-
PCR–negative patient. Drug treatment for this group of
patients may be withheld or delayed, especially if effective
and reliable treatment has not been found.
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